PVLA - Palvella Therapeutics, Inc

PVLA - Palvella Therapeutics, Inc

https://palvellatx.com

Buy Momentum: Bearish

Recent News

Powered by Alpha Vantage

Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations - Palvella Therapeutics ( NASDAQ:PVLA )

Benzinga • 4 hours, 18 minutes ago • score: 0.13

Phase 2 TOIVA trial successfully met recruitment target, enrolling 16 subjects at leading vascular anomaly centers; top-line data expected in mid-December 2025

Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences

GlobeNewswire • 2 weeks, 4 days ago • score: 0.08

WAYNE, Pa., Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- ( Nasdaq: PVLA ) Palvella Therapeutics, Inc. ( Palvella ) , a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there ...

Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025 - Palvella Therapeutics ( NASDAQ:PVLA )

Benzinga • 1 month, 1 week ago • score: 0.10

WAYNE, Pa., Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- PVLA Palvella Therapeutics, Inc. ( Palvella ) , a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no ...

This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Almonty Indus ( NASDAQ:ALM ) , Adagene ( NASDAQ:ADAG )

Benzinga • 1 month, 1 week ago • score: 0.41

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference - Palvella Therapeutics ( NASDAQ:PVLA )

Benzinga • 1 month, 1 week ago • score: 0.14

WAYNE, Pa., Aug. 05, 2025 ( GLOBE NEWSWIRE ) -- PVLA Palvella Therapeutics, Inc. ( Palvella ) , a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no Food ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

None

52W High

$58.22

52W Low

$11.17

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

N/A

Valuation

Attractive

As of 2024-03-31 (Overview)

Trailing P/E (<15 better)

9.92

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

N/A

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

N/A

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

17.50%

Institutions (25–75% balanced)

36.51%

Shares Outstanding

11,221,300

Float

3,351,800

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

As of 2024-03-31 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

0

EPS (TTM)

1.97

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

N/A

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

5.2203

Previous

5.2507

Trend

Falling

Signal Cross

No cross

As of

Sep. 05, 2025